Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial
JAAD. 2024. Epub ahead of print DOI: 10.1016/j.jaad.2024.09.074
Werth et al. demonstrated that iberdomide significantly improved cutaneous lupus erythematosus (CLE) outcomes, particularly in subacute and chronic CLE patients, by reducing Cutaneous Lupus Area and Severity Index Activity (CLASI-A) scores. The study showed continued efficacy through 24 weeks, with the 0.45 mg dose providing the greatest improvement in patients with severe baseline scores, and iberdomide was well-tolerated over 104 weeks.
This phase 2 trial aimed to assess the efficacy and safety of iberdomide, a cereblon modulator targeting transcription factors Ikaros and Aiolos implicated in lupus pathogenesis. Patients were randomised across three doses of iberdomide and placebo, with treatment effects evaluated at weeks 4, 24, 52 and 104.